VRTX · Vertex Pharmaceuticals Incorpor
$515.44
+0.17% last session
End-of-day data · close of 2026-09-11
Market cap
$130B
Enterprise value
$125B
Trailing P/E
30.0
Forward P/E
25.4
Dividend yield
—
Beta
0.32
Avg volume
1M
Employees
6K
Daily Change %
0.17%
5 Days Change
-4.58%
10 Days Change
-4.30%
30 Days Change
-1.61%
60 Days Change
7.36%
Month to Day Change
-4.84%
Year to Day Change
14.95%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — VRTX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-05
Latest call per bank · past 12 months
Barclays
Overweight$617
+19.9% vs priceUBS
Buy$585
+13.7% vs priceRBC Capital
Outperform$570
+10.8% vs priceMorgan Stanley
Overweight$616
+19.7% vs priceBank of America
Buy$598
+16.2% vs priceCitigroup
Buy$585
+13.7% vs priceJefferies
Buy$580
+12.7% vs priceWells Fargo
Overweight$515
+0.1% vs priceJP Morgan
Overweight$530
+3.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-05 | Truist Securities | Maintains | Buy | $560 → $565 |
| 2026-08-05 | Barclays | Maintains | Overweight | $615 → $617 |
| 2026-08-04 | TD Cowen | Maintains | Buy | $525 → $550 |
| 2026-08-04 | Cantor Fitzgerald | Maintains | Overweight | $590 → $595 |
| 2026-08-04 | Canaccord Genuity | Maintains | Hold | $436 → $442 |
| 2026-07-13 | UBS | Maintains | Buy | $545 → $585 |
| 2026-07-13 | Truist Securities | Maintains | Buy | $542 → $560 |
| 2026-07-07 | RBC Capital | Maintains | Outperform | $543 → $570 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 44 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 0.9% above the 50-day MA ($510.65).
- Price vs 200-day MA: Trading 10.1% above the 200-day MA ($468.02).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-5.96) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($376.62) and high ($557.96).
VRTX Price Chart
Loading chart for VRTX…
Fundamentals
About Vertex Pharmaceuticals Incorpor
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
More in Biotechnology
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
ROIV
Roivant Sciences Ltd.
$30B 92.7% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.